Publications in collaboration with researchers from Hospital de l'Esperit Sant (1)

2010

  1. Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer

    Chemotherapy, Vol. 56, Núm. 2, pp. 142-146